Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
Harvard Bioscience (Nasdaq: HBIO) has scheduled its third quarter 2024 financial results announcement for November 7, 2024, before market opening. The company will host a conference call at 8:00 AM ET to discuss the results. Participants wanting to ask questions must pre-register to receive dial-in information and a PIN. An audio-only webcast option is also available through the company's investor website, where the earnings release and related presentation materials will be accessible.
Harvard Bioscience (Nasdaq: HBIO) ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 per il 7 novembre 2024, prima dell'apertura del mercato. L'azienda ospiterà una chiamata in conferenza alle 8:00 AM ET per discutere i risultati. I partecipanti che desiderano porre domande devono registrarsi in anticipo per ricevere le informazioni per la chiamata e un PIN. È disponibile anche un'opzione di webcast solo audio attraverso il sito web per gli investitori dell'azienda, dove sarà accessibile il comunicato sugli utili e i materiali di presentazione correlati.
Harvard Bioscience (Nasdaq: HBIO) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el 7 de noviembre de 2024, antes de la apertura del mercado. La compañía llevará a cabo una llamada de conferencia a las 8:00 AM ET para discutir los resultados. Los participantes que deseen hacer preguntas deben preinscribirse para recibir la información de acceso y un PIN. También está disponible una opción de webcast solo de audio a través del sitio web de inversores de la compañía, donde se podrá acceder al comunicado de ganancias y a los materiales de presentación relacionados.
하버드 바이오사이언스(Nasdaq: HBIO)는 2024년 3분기 재무 결과 발표를 2024년 11월 7일 시장 개장 전에 예정하고 있습니다. 회사는 동부 표준시 오전 8시에 결과를 논의하기 위한 컨퍼런스 콜을 개최할 예정입니다. 질문을 하고 싶은 참가자는 다이얼인 정보와 PIN을 받기 위해 사전 등록해야 합니다. 오디오 전용 웹캐스트 옵션도 회사의 투자자 웹사이트를 통해 제공되며, 여기에서 수익 발표 및 관련 발표 자료에 접근할 수 있습니다.
Harvard Bioscience (Nasdaq: HBIO) a prévu l'annonce de ses résultats financiers pour le troisième trimestre 2024 le 7 novembre 2024, avant l'ouverture du marché. L'entreprise tiendra une conférence téléphonique à 8h00 ET pour discuter des résultats. Les participants souhaitant poser des questions doivent s'inscrire à l'avance pour recevoir des informations de connexion et un PIN. Une option de webdiffusion audio uniquement est également disponible via le site Web des investisseurs de l'entreprise, où le communiqué de presse et les documents de présentation associés seront accessibles.
Harvard Bioscience (Nasdaq: HBIO) hat die Bekanntgabe seiner finanziellen Ergebnisse für das dritte Quartal 2024 auf den 7. November 2024 vor der Markteröffnung angesetzt. Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Teilnehmer, die Fragen stellen möchten, müssen sich im Voraus registrieren, um Anrufinformationen und eine PIN zu erhalten. Eine Audio-Only-Webcast-Option ist ebenfalls über die Investorenseite des Unternehmens verfügbar, wo die Pressemitteilung und die zugehörigen Präsentationsmaterialien zugänglich sein werden.
- None.
- None.
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Jennifer Cote
Chief Financial Officer
(508) 893-3120
Investors Contact:
Three Part Advisors
Sandy Martin
HBIO@threepa.com
(214) 616-2207
FAQ
When will Harvard Bioscience (HBIO) release Q3 2024 earnings?
What time is Harvard Bioscience's (HBIO) Q3 2024 earnings call?
How can investors join Harvard Bioscience's (HBIO) Q3 2024 earnings call?
